c59367_fwp.htm -- Converted by SEC Publisher, created by BCL Technologies Inc., for SEC Filing
Pricing Term Sheet
Term sheet    Registration Statement No. 333-143867 
To prospectus dated June 19, 2007 and    Filed Pursuant to Rule 433 of the Securities Act of 1933 
preliminary prospectus supplement dated November 12, 2009     

Free Writing Prospectus Dated November 12, 2009

$750,000,000
Quest Diagnostics Incorporated

$500,000,000 4.750% Senior Notes due 2020
$250,000,000 5.750% Senior Notes due 2040

4.750% Senior Notes due 2020     
     
Issuer:    Quest Diagnostics Incorporated 
     
Principal Amount:    $500,000,000 
     
Maturity Date:    January 30, 2020 
     
Trade Date:    November 12, 2009 
     
Original Issue Date (Settlement):    November 17, 2009 
     
Interest Accrual Date:    November 17, 2009 
     
Issue Price (Price to Public):    98.491% 
     
Yield:    4.938% 
     
Interest Rate:    4.750% per annum 
     
Interest Payment Period:    Semi-annual 
     
Interest Payment Dates:    Each January 30 and July 30, commencing July 30, 2010 
     
Treasury Benchmark:    3.625% due August 15, 2019 
     
Spread to Benchmark:    T+150 bps 
     
Benchmark Yield:    3.438% 

Optional Make-Whole Redemption:    At any time and from time to time, the notes will be redeemable, as a whole or in 
    part, at the option of Quest Diagnostics, on at least 30 days, but not more than 60 
    days, prior notice mailed to the registered address of each holder of the notes, at a 
   
redemption price equal to the greater of:
 
     •  100% of principal amount of the Notes to be redeemed, and 
 
     •  the sum of the present values of the remaining scheduled payments 
      discounted, on a semiannual basis, assuming a 360-day year consisting of 
      twelve 30-day months, at the applicable treasury rate plus 25 basis points, 
 
    plus accrued interest to the date of redemption which has not been paid. 
 
CUSIP:    74834L AP5 
 
ISIN:    US74834LAP58 
 
Joint Book-Running Managers:    Banc of America Securities LLC 
    Morgan Stanley & Co. Incorporated 
    RBS Securities Inc. 
    Wells Fargo Securities, LLC 
 
Co-Managers:    Barclays Capital Inc. 
    Calyon Securities (USA), Inc. 
    J.P. Morgan Securities Inc. 
   
Mitsubishi UFJ Securities (USA), Inc.
    U.S. Bancorp Investments, Inc. 
 
Global Settlement:    Through The Depository Trust Company, Euroclear or Clearstream, Luxembourg 

The issuer has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling Banc of America Securities LLC toll free at 1-800-294-1322; Morgan Stanley & Co. Incorporated toll free at 1-866-718-1649; RBS Securities Inc. toll free at 1-866-884-2071; and Wells Fargo Securities, LLC toll free at 1-800-326-5897.

5.750% Senior Notes due 2040       
     
Issuer:    Quest Diagnostics Incorporated 
     
Principal Amount:    $250,000,000 
     
Maturity Date:    January 30, 2040 
     
Trade Date:    November 12, 2009 
     
Original Issue Date (Settlement):    November 17, 2009 
     
Interest Accrual Date:    November 17, 2009 
     
Issue Price (Price to Public):    97.228% 
     
Yield:    5.947% 
     
Interest Rate:    5.750% per annum 
     
Interest Payment Period:    Semi-annual 
     
Interest Payment Dates:    Each January 30 and July 30, commencing July 30, 2010 
     
Treasury Benchmark:    4.250% due May 15, 2039 
     
Spread to Benchmark:    T+155 bps 
     
Benchmark Yield:    4.397% 
     
Optional Make-Whole Redemption:    At any time and from time to time, the notes will be redeemable, as a whole or 
    part, at the option of Quest Diagnostics, on at least 30 days, but not more than 60 
    days, prior notice mailed to the registered address of each holder of the notes, at 
   
redemption price equal to the greater of:
     •  100% of principal amount of the Notes to be redeemed, and 
     •  the sum of the present values of the remaining scheduled payments 
      discounted, on a semiannual basis, assuming a 360-day year consisting of 
      twelve 30-day months, at the applicable treasury rate plus 25 basis points, 
    plus accrued interest to the date of redemption which has not been paid. 
     
CUSIP:    74834L AQ3 
     
ISIN:    US74834LAQ32 
     
Joint Book-Running Managers:    Banc of America Securities LLC 
    Morgan Stanley & Co. Incorporated 
    RBS Securities Inc. 
    Wells Fargo Securities, LLC 
     
Co-Managers:    Barclays Capital Inc. 
    Calyon Securities (USA), Inc. 
    J.P. Morgan Securities Inc. 
   
Mitsubishi UFJ Securities (USA), Inc.
   
U.S. Bancorp Investments, Inc.
     
Global Settlement:
  
Through The Depository Trust Company, Euroclear or Clearstream, Luxembourg

The issuer has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling Banc of America Securities LLC toll free at 1-800-294-1322; Morgan Stanley & Co. Incorporated toll free at 1-866-718-1649; RBS Securities Inc. toll free at 1-866-884-2071; and Wells Fargo Securities, LLC toll free at 1-800-326-5897.

Any disclaimers or other notices that may appear below are not applicable to this communication and should be disregarded. Such disclaimers or other notices were automatically generated as a result of this communication being sent via Bloomberg or another email system.